Plain-English translation of NCT00258570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking for genetic clues that help explain why some people develop idiopathic pulmonary fibrosis (IPF), a serious lung disease where healthy lung tissue gradually turns into scar tissue. Researchers will collect blood samples and study your genetic information to identify which genes may make someone more likely to develop this condition. By understanding these genetic factors, doctors hope to better predict who is at risk and eventually develop better treatments.
IPF is a serious disease where lung tissue scars over time, making it hard to breathe, but doctors still don't fully understand why it happens or why it affects some people more than others. This study aims to discover the genetic differences that make certain people vulnerable to developing the condition, which could lead to new ways to predict, prevent, or treat the disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the research center for an evaluation, which will likely include a physical exam, breathing tests, and chest imaging if not recently done. You will provide a blood sample so researchers can study your genetic information. The study is primarily observational, meaning researchers are studying your genes and disease information rather than testing a new medication or treatment on you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Enrollment target
~2,000 participants
Started
January 2003
Primary completion
July 2035
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michelle F MacPherson, MAT
University of Pittsburgh, Simmons Center for ILD
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.